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Choosing outcomes relevant to patients and healthcare 
professionals is essential if clinical trial results are 
to be translated into practice. A frequent frustration 
encountered in summarising the clinical effectiveness 
of treatments for urological cancers is heterogeneity in 
the outcomes reported. This refers to two interrelated 
problems: inconsistency, where different outcomes are 
reported across different studies, and variability, where 
the same outcomes are reported across studies but are 
defined or measured differently. Outcome inconsistency 
and variability make comparing, contrasting, synthesising 
and interpreting the results of different studies on the 
same topic more complicated than it ought to be. The 
implications of outcome reporting heterogeneity come 
into sharp relief in systematic reviews of interventions. For 
instance, in a cohort of Cochrane systematic reviews, 40% 
of reviewers noted problems due outcome inconsistency (1). 
This problem is of particular importance when meta-
analysis (the statistical pooling of aggregated data from 
two or more studies, providing more power and precision) 
is either not possible, or worse, done inappropriately 
regardless. Systematic reviews are a cornerstone of the 
Evidence Based Medicine (EBM) movement and are an 
essential component in creating clinical practice guideline 
(CPG) recommendations—which inform patient, clinician 
and policy decision-making. To arrive at CPG treatment 
recommendations, urology guideline making bodies such 
as the European Association of Urology (EAU) rely on 
published or commissioned systematic reviews, ideally of 
RCTs, but frequently incorporating various study designs. 
There are numerous examples of outcome reporting 
heterogeneity hindering guideline panels from making 
evidence-based recommendations throughout urology 
oncology and some examples from prostate and bladder 
cancer are outlined below.
For clinical trial results to be useful the views of a 
variety of stakeholders, particularly patients, must be 
considered. Localised prostate cancer patients and health 
care professionals alike prioritise oncological outcomes, 
such as survival and progression, as well as health related 
quality of life (HRQoL) outcomes, encompassing bowel, 
urinary and sexual function, as among the most important 
outcomes to be measured in prostate cancer research 
(2,3). Given that there is a lack of evidence on oncological 
superiority in currently available localised prostate cancer 
treatments, the EAU prostate cancer guideline panel 
commissioned a systematic review to ascertain HRQoL and 
functional outcomes after any intervention for localised 
prostate cancer (4). Numerous patient-reported outcome 
measures (PROMs) were found purporting to assess 
HRQoL and various aspects of the functional outcomes 
(e.g., EPIC, UCLA-PCI, EORTC QLQ-30/PR25, PCOS) 
across the 18 included studies. Not every tool covers every 
functional domain and the measurement scales are often 
non-commensurable. Meta-analysis was not possible, 
and interpretation was difficult. Similarly, in a Health 
Technology Assessment including 54 studies comparing 
laparoscopic with robotic prostatectomy, Ramsay et al. (5) 
(page 84) noted that a “…specific methodological limitation 
that frustrated pooled analysis was the use of differing definitions 
and measures of functional outcomes for both urinary and 
erectile dysfunction. The variety of different ways of measuring 
dysfunction reduced the ability to compare data or to conduct a 
comprehensive meta-analysis”. A further review of PROMs 
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used in prostate cancer research found 15 disease specific or 
generic tools have been used and that none were established 
enough to be relevant for long term prostate cancer 
survivorship (6). The results of these three examples all 
point to the same conclusion: it is difficult to say anything 
meaningful about the comparative effectiveness of the 
variety of available treatments for localised prostate cancer 
on long term functional outcomes.
Two systematic reviews commissioned by the EAU 
Guidelines Office muscle invasive bladder cancer (MIBC) 
panel demonstrated outcome inconsistency and variability. 
Veskimäe et al. (7) reviewed oncological and functional 
outcomes of pelvic organ sparing radical cystectomy 
compared with standard radical cystectomy in women 
undergoing curative surgery and orthotopic neobladder 
substitution for bladder cancer. In the main results table, 
the column headers are ‘local recurrence’, ‘time to local 
recurrence’, ‘metastatic recurrence’, ‘disease specific 
survival’ and ‘overall survival’. Of the 15 included studies 
reporting on oncological outcomes, only one reported 
all these outcomes, and no single oncology outcome was 
reported in all the studies. Indeed ‘not reported’ is by far 
the most frequently occurring data in the table’s cells. No 
meta-analysis was possible, and a cumbersome narrative 
synthesis was required. Hernández et al. (8) systematically 
reviewed sexual function preserving cystectomy versus 
standard radical cystectomy in men. Continence was 
frequently measured across the 12 included studies, but 
the time point of measurement (6, 1–9, 12, 48 months) 
and the method of measurement [self-reported, number of 
pads, pad test (volume), voiding diary, and Bladder Cancer 
Index questionnaire] were variable. The data relating to 
these outcomes are qualitatively different from each other, 
so statistically combining them is not possible, and even 
if standardisation were possible, the differing time points 
would make a pooled average statistic meaningless and 
misleading.
The previous examples have been situated in the 
context of difficulties in recommendation-making for 
guideline panels. However, outcome heterogeneity is also 
problematic for initiatives seeking to address improvement 
through benchmarking value across providers, such 
as the International Consortium for Health Outcome 
Measurement (ICHOM) (3,9), and for big data projects 
such as Prostate PIONEER where consistency in outcome 
definitions and measurements are key considerations in 
data harmonisation with multiple sources such as RCTs, 
observational studies, institutional registries, and claims 
databases all contributing data (10).
Core outcome sets (COSs) are a solution to heterogeneity 
in outcomes reporting. A COS is an agreed standardised 
collection of outcomes which should be reported as a 
minimum in all trials for a specific clinical area (11). 
The Core Outcome Measures for Effectiveness Trials 
(COMET) initiative is a hub for COS development. They 
provide guidance, develop methodological standards (12) 
and reporting guidelines (13,14) as well as maintain a 
searchable database of ongoing and completed COS 
projects. Importantly, COMET note that where COS 
exist, researchers should not feel restricted to measure 
only the core outcomes, other outcomes may be collected 
additionally.
The development of a COS proceeds by first identifying 
what outcomes are important, then how they should be 
measured. An essential initial step is to define the COS 
scope, for which the first three elements of the Patient 
Intervention Comparator Outcomes (PICO) structure is 
useful. Consideration should also be given to the intended 
end uses of the COS, for example in RCTs only, routine 
care only, or both. Then, the COMET database (http://
www.comet-initiative.org/Studies) should be checked 
to ensure no duplication of effort or to potentially offer 
collaboration where an ongoing COS is already registered.
If a new COS is to be initiated then a study protocol 
should be developed according to the Core Outcome Set 
Standard Protocol (COS-STAP) items statement and the 
study registered with COMET (14). Next, various research 
methods such as systematic reviews and stakeholder 
interviews are used to generate a comprehensive list of 
outcomes potentially important to a variety of stakeholders, 
such as surgeons, oncologists, nurses and patients. A 
consensus exercise to prioritise the most important 
outcomes is then recommended using methods such as 
a Delphi survey, and often culminating in a face-to-face 
consensus meeting, where a final list of core outcomes 
is agreed and ratified (11). Finally, the COS is usually 
reported in a journal manuscript and reporting according 
to the Core Outcome Set Standards for Reporting (COS-
STAR) statement (13) is encouraged. Then attention should 
turn to uptake of the COS among the clinical and research 
communities. However, implementation is rarely linear 
and other efforts, such as encouraging uptake through 
endorsement from journal editors, trial funders, trial 
registries and regulatory authorities is likely to be more 
successful than publication alone.
Once the core outcomes are known, further review 
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and consensus work is required to assess and recommend 
the most appropriate definitions and measurement tools. 
Definitions for clinician reported outcomes may require 
reviewing existing definitions used in published studies and 
seeking consensus from stakeholders on which of those 
definitions is most appropriate, and other considerations 
like the timepoint(s) of measurement. For PROMs 
additional work on assessing the psychometric properties 
and feasibility of use is required prior to further consensus 
work. Extensive guidance on systematically reviewing 
and evaluating PROMs is available from the COnsensus-
based Standards for the selection of health Measurement 
Instruments (COSMIN) group (15,16).
Although COS require effort to develop, promote and 
engage the clinical specialty community, experience from 
other disciplines demonstrate that improvement is possible. 
For instance, the Outcome Measures in Rheumatology 
(OMERACT) group involved a variety of stakeholders 
in identifying and prioritising outcomes in antirheumatic 
drugs for rheumatoid arthritis (RA) trials. OMERACT 
published their first RA COS in 1994 (17). Since then 
there has been a consistent increase in the use of the RA 
COS and 81% of registered and completed RA trials now 
report the COS, and selective outcome reporting has 
decreased (18). Also, the CoRe Outcomes in Women’s and 
Newborn health (CROWN) initiative have demonstrated 
a targeted and organised approach to implementing their 
COS by facilitating a consortium of over 80 gynaecology-
obstetrics related journals to publicise relevant COS 
through editorials, publish the various COS, and endorse 
the use of COS in studies submitted to their journals (19). 
Finally, the Cochrane Skin group, who manage Cochrane 
reviews in the dermatology setting, have embedded a COS 
initiative within their review group which aims to facilitate 
implementation (20).
Outcome reporting heterogeneity is problematic for 
urology cancer research and decision-making at many 
levels. COS are proposed as a solution. Fortunately, a 
supportive methodological hub and a wealth of applied 
research examples are available. Initiatives from other 
disciplines show that improvement is possible and there is 
no reason why the urology community cannot organise in a 
concerted effort to reduce outcome reporting inconsistency 
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